Safety of enhanced renin-angiotensin-aldosterone system inhibition with aliskiren in nondiabetic patients with chronic kidney disease

Polskie Archiwum Medycyny Wewnetrznej

Volumn 123, Issue 5, 2013, Pages 221-227

  Lizakowski, Sławomir ^a   Tylicki, Leszek ^a   Rutkowski, Przemysław ^a   Renke, Marcin ^a   Sulikowska, Beata ^b   Heleniak, Zbigniew ^a   Donderski, Rafał ^b   Bednarski, Rafał ^b   Przybylska, Milena ^a   Manitius, Jacek ^b   Rutkowski, Bolesław ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Aliskiren; Chronic kidney disease; Proteinuria; Renin angiotensin aldosterone system

Indexed keywords

ALISKIREN; CREATININE; EPLERENONE; PERINDOPRIL; POTASSIUM; PRORENIN; RENIN; TELMISARTAN; TRANSFORMING GROWTH FACTOR BETA1; AMIDE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; DIURETIC AGENT; FUMARIC ACID DERIVATIVE;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MALE; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY; OPEN STUDY; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; URINARY EXCRETION; CHRONIC DISEASE; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; KIDNEY DISEASES; MIDDLE AGED; PATIENT SAFETY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; AMIDES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; CHRONIC DISEASE; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FUMARATES; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PATIENT SAFETY; RENIN-ANGIOTENSIN SYSTEM; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84880097102     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1726     Document Type: Article

References (20)

1. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999; 354: 359-364.
2. Lewis EJ, Hunsicker LG, Clarke WR, et al.; Collaborative Styudy Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345: 851-860.
3. Stompór T, Olszewski A, Kierzkowska I. Can we prolong life of patients with advanced chronic kidney disease: what is the clinical evidence? Pol Arch Med Wewn. 2011; 121: 88-93.
4. Lizakowski S, Tylicki L, Renke M, et al. Aliskiren and perindopril reduce the levels of transforming growth factor-β in patients with non-diabetic kidney disease. Am J Hypertens. 2012; 25: 636-639.
5. Tylicki L, Rutkowski P, Renke M, Rutkowski B. Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney. Kidney Int. 2007; 72: 1164-1165.
6. Persson F, Rossing P, Parving HH. Direct renin inhibition in chronic kidney disease. Br J Clin Pharmacol. 2012 Dec 25. doi: 10.1111/bcp.12 072. [Epub ahead of print].
7. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009; 4: 542-551.
8. Thomas CM, Yong QC, Seqqat R, et al. Direct renin inhibition prevents cardiac dysfunction in a diabetic mouse model: comparison with an angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor. Clin Sci (Lond). 2013; 124: 529-541.
9. Tylicki L, Lizakowski S, Rutkowski B. Renin-angiotensin-aldosterone system blockade for nephroprotection: current evidence and future directions. J Nephrol. 2012; 25: 900-910.
10. Tylicki L, Lizakowski S, Rutkowski P, et al. The enhanced renin-angiotensin-aldosteron system pharmacological blockade - which is the best? Kidney Blood Press Res. 2012; 36: 335-343.
11. Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther. 2012; 30: 156-166.
12. Onuigbo MA. Can ACE inhibitors and angiotensin receptor blockers be detrimental in CKD patients? Nephron Clin Pract. 2011; 118: 407-419.
13. Bakris G, Siomos M, Richardson D, et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int. 2000; 58: 2084-2092.
14. Izzo JL Jr. Benefits of antihypertensive drugs when blood pressure is below 140/90 mmHg. Pol Arch Med Wewn. 2011; 121: 303-309.
15. Danser AH. The increase in renin during renin inhibition: does it result in harmful effects by the (pro)renin receptor? Hypertens Res. 2010; 33: 4-10.
16. Gansevoort R, De Zeeuw D, De Jong P. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int. 1994; 45: 861-867.
17. Mann J F, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008; 372: 547-553.
18. Parving HH, Brenner BM, McMurray JJ, et al.; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012; 367: 2204-2213.
19. Huang Y, Noble NA, Zhang J, Xu C, Border WA. Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int. 2007; 72: 45-52.
20. Schefe JH, Unger T, Funke-Kaiser H. PLZF and the (pro)renin receptor. J Mol Med (Berl). 2008; 86: 623-627.